Natera, Inc. ($NTRA) Stock Forecast: Down 3.8% Today

What is Natera, Inc.?

Natera (NASDAQ: NTRA) specializes in genetic testing and molecular diagnostics, particularly in cancer detection and personalized medicine. The stock faced a significant bearish movement today.

Why is Natera, Inc. going down?

NTRA stock is down 3.8% on Dec 11, 2025 16:11

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera (NASDAQ: NTRA) PALLAS: Signatera MRD‑positive group shows 13.4‑21.5 hazard ratios

Natera, Inc. announced initial results from the Phase III PALLAS study, showing that its Signatera molecular residual disease (MRD) test provides powerful post-surgical prognostic information for patients with high and intermediate risk HR+/HER2- breast cancer. The study found that MRD-positive patients had significantly worse outcomes and substantially elevated hazard ratios for distant recurrence compared to MRD-negative patients, supporting the integration of MRD testing into routine post-surgical risk assessment. These findings indicate a potential shift towards personalized treatment strategies, where MRD status could guide the intensity and type of therapy.

https://www.stocktitan.net/news/NTRA/phase-iii-pallas-study-shows-signatera-tm-mrd-testing-provides-fnd8n30z03p6.html

Natera acquires Foresight Diagnostics for up to $450M

Natera has acquired cancer testing company Foresight Diagnostics for up to $450 million. This acquisition, comprising $275 million upfront and up to $175 million in milestone payments, strengthens Natera's position in solid tumor molecular residual disease detection, especially in lymphoma. Foresight's PhasED-Seq technology will be integrated into Natera's Signatera platform, with a clinical launch expected in 2026.

https://www.medtechdive.com/news/Natera-Foresight-Diagnostics-acquisition-cancer-testing/807478/

Natera director Chapman sells shares for $1.06 million

Rowan E Chapman, a director at Natera, Inc. (NASDAQ:NTRA), sold 4,366 shares for $1.06 million on December 5, 2025, while also exercising options to acquire 4,000 shares for $128,600. This transaction occurred as the company shows strong momentum, with its stock trading near a 52-week high despite being considered above its Fair Value by InvestingPro. Natera has also recently reported strong Q3 results and acquired Foresight Diagnostics, garnering positive analyst ratings.

https://www.investing.com/news/insider-trading-news/natera-director-chapman-sells-shares-for-106-million-93CH-4399855

Guggenheim Capital LLC Sells 4,628 Shares of Natera, Inc. $NTRA

Guggenheim Capital LLC has reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 13.8%, selling 4,628 shares, yet still holding 29,007 shares valued at $4.9 million. This transaction contrasts with significant increases in institutional investor positions, with large institutions now owning 99.90% of the stock. Meanwhile, company insiders, including CEO Steven Chapman, have been selling shares, while Wall Street analysts largely maintain a "Moderate Buy" rating with a consensus price target of $223.53.

https://www.marketbeat.com/instant-alerts/filing-guggenheim-capital-llc-sells-4628-shares-of-natera-inc-ntra-2025-12-08/

Jump Financial LLC Purchases 18,821 Shares of Natera, Inc. $NTRA

Jump Financial LLC increased its stake in Natera, Inc. by 8.7% during the second quarter, acquiring an additional 18,821 shares, bringing its total holdings to 234,859 shares valued at approximately $39.68 million. Despite Natera missing EPS estimates in its latest quarter, revenue significantly beat expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $223.53. However, the company has seen substantial insider selling, with the CEO and other insiders disposing of shares worth over $63 million in the last 90 days.

https://www.marketbeat.com/instant-alerts/filing-jump-financial-llc-purchases-18821-shares-of-natera-inc-ntra-2025-12-07/

Trending Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.8% Today

Apache Corporation ($APA) Stock Forecast: Down 5.1% Today

Natera, Inc. Price History

08.07.2025 - NTRA Stock was up 16.5%

• Natera (NTRA) reported a Q2 loss but surpassed revenue estimates, indicating strong top-line growth.
• The positive revenue surprise likely boosted investor confidence in the company's long-term growth prospects.
• Investors may be optimistic about Natera's future potential in the genetic testing market, driving the bullish movement in the stock.
• The market may be interpreting the revenue beat as a sign of Natera's ability to capitalize on the growing demand for personalized healthcare solutions, leading to the bullish momentum in the stock.

09.06.2025 - NTRA Stock was up 5.1%

• There was a strong bullish movement in Natera Inc. today.
• The rise in revenues and profits of a competitor in the AI tools and data services sector may have positively influenced market sentiment towards Natera Inc.
• Investors show optimism about Natera Inc.'s potential for revenue growth and improved margins, similar to the success seen by its competitor.
• The increasing adoption of AI technologies in the healthcare and biotechnology industries could be driving positive investor sentiment towards companies like Natera Inc.

13.10.2024 - NTRA Stock was up 17.2%

• Natera (NTRA) stock experienced a strong bullish movement following the release of its third-quarter financial results.
• Analysts increased their forecasts for Natera after the company reported a quarterly loss that was lower than expected and topped revenue estimates.
• The options market also indicated a bullish sentiment towards Natera, with significant funds taking a positive position in the company.
• The positive performance of Natera stock could be attributed to the company's strong financial results and optimistic revenue guidance for the future, leading to increased investor confidence and driving the stock price higher.

25.01.2025 - NTRA Stock was down 5.1%

• Natera (NTRA) showed significant bearish movement today.
• Comparison with Gilead Sciences (GILD) in the medical stocks sector may have revealed Natera's underperformance, influencing a negative market sentiment.
• Investors are expressing concerns about Natera's competitive position in the sector, potentially impacting its stock price adversely.
• It is likely that Natera encountered specific challenges or setbacks, prompting investors to sell shares and leading to the bearish movement.

18.11.2024 - NTRA Stock was down 5.3%

• Despite the "Golden Cross" signal indicating a bullish trend, Natera (NTRA) has faced bearish movement recently.
• While surpassing the resistance at the 20-day simple moving average could signal short-term bullish momentum, today's bearish movement suggests other influencing factors.
• Factors such as broader market conditions, company-specific news, or profit-taking activities may be contributing to the downward pressure on Natera's stock price.
• Traders should consider technical signals and external factors when deciding on transactions involving Natera (NTRA) in the current market climate.

16.09.2025 - NTRA Stock was up 5.2%

• Natera has demonstrated impressive performance over the last 5 years, surpassing market performance by 5.63% annually, likely attracting investors seeking high returns.
• The company's emphasis on cutting-edge genetic testing technologies and its market capitalization of $23.35 billion have bolstered investor confidence and a positive market outlook.
• The favorable sentiment surrounding Natera's historical performance and growth prospects could have triggered heightened buying activity, resulting in today's notable bullish movement in the stock.

11.11.2025 - NTRA Stock was down 3.8%

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

07.10.2025 - NTRA Stock was down 5.0%

• Natera exceeded revenue predictions but faced a notable loss in Q3 earnings, potentially influencing the stock's downturn.
• Worries about Natera's profitability outlook may have prompted investors to sell off the company's shares.
• The combination of uneven performance and a significant earnings shortfall could have eroded investor faith in Natera's future growth, triggering adverse market movements.

20.01.2025 - NTRA Stock was down 5.3%

• Over the past 5 years, Natera has outperformed the market significantly with an average annual return of 36.12%.
• Despite breaking above the 20-day moving average recently, suggesting a positive momentum, the stock saw a bearish movement today.
• The bearish movement may be due to profit-taking by investors or broader market factors affecting the stock negatively.
• Investors should monitor any upcoming developments related to Natera to determine if the bearish trend is a temporary correction or a more sustained shift in market sentiment.

11.01.2025 - NTRA Stock was down 3.4%

• Strong performance by Natera in the past 5 years may have prompted profit-taking by investors, resulting in a decline in the stock.
• Investors who had gained significantly from Natera's stock in the past might have opted to divest, contributing to the downward trend in the stock price.
• The market sentiment appears to have turned bearish possibly due to perceived overvaluation following the impressive performance, leading to a sell-off and the observed decline in stock price today.

23.03.2025 - NTRA Stock was up 5.1%

• Demonstrating a remarkable performance over the last five years, surpassing the market by 19.34% annually, has attracted investors interested in high returns.
• With a focus on genetic testing and a market capitalization of $20.02 billion, Natera holds a prominent position within the biotech sector, instilling confidence in investors.
• The upward trend in NTRA's stock performance today may be linked to the ongoing positive outlook regarding the company's growth potential and market outperformance.

28.01.2025 - NTRA Stock was down 5.5%

• The bearish movement in NTRA today could be attributed to the reported Q4 loss, despite topping revenue estimates.
• Investors may have reacted negatively to the earnings surprise and uncertainties about the company's future profitability.
• The market sentiment might have shifted due to concerns raised by the financial performance, leading to a sell-off of Natera shares.
• The slight miss in earnings and revenue could have caused investors to reassess the stock's valuation and potential growth prospects, resulting in the bearish movement observed today.